title: Is it worthy of switching to PegIFN alfa-2a in patients achieving virological suppression with entecavir?
authors.affiliation: Department of Infectious Diseases, Shekou People's Hospital, Shenzhen, China. Electronic address: chuanghongwu@aliyun.com.
authors.forename: Chuanghong
authors.initials: C
authors.lastname: Wu
authors.affiliation: Department of Infectious Diseases, Shekou People's Hospital, Shenzhen, China; Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
authors.forename: Winston
authors.initials: W
authors.lastname: Dunn
mesh_terms: D005260:Female; D006147:Guanine / Q000031:analogs & derivatives*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006513:Hepatitis B e Antigens / Q000097:blood*; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*
chemical_list: D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D006147:Guanine